

Foundations in Immunotherapy in the Oncology Population

Strategies for Clinical Application
& Patient Management

Wednesday, January 28, 2026
8:00 a.m. — 4:45 p.m. (EST)
Virtual Symposium



Memorial Sloan Kettering
Cancer Center



Overview

Immunotherapeutics have transformed the treatment landscape for patients with both solid tumors and hematologic malignancies. Since the landmark approval of ipilimumab, rapid and ongoing advancements in immunotherapy have continued to revolutionize clinical practice.

This one-day live virtual CME program, presented by **Memorial Sloan Kettering Cancer Center (MSK)**, offers a comprehensive review of **foundational concepts** and **emerging advances in cancer immunotherapy**, tailored to the educational needs of physicians, advanced practice providers (APPs), and allied health professionals. Faculty experts will highlight clinical **applications across solid and hematologic cancers**, as well as strategies for recognizing and managing toxicity—including **immune-related adverse events (irAEs)** associated with immune checkpoint inhibition.

Presentations will cover the **fundamentals of immune checkpoint blockade** and **CAR T-cell therapy**, along with updates in **TIL and BiTE therapies, novel combination approaches**, and **algorithmic management of irAEs**. Toxicity management will be reinforced through **case-based discussions** illustrating common, rare, and severe presentations.

The goal of this program is to **improve patient outcomes** by advancing understanding of cancer immunology and enhancing the effective, evidence-based application of immunotherapeutic strategies in clinical practice.

This is a virtual-only program. Detailed access instructions will be provided prior to the start of the program. Participants will receive access to an **online syllabus** after the symposium concludes, which will include video recordings of the faculty presentations.

For full details and registration, visit:

msk.org/ImmunoOncSymposium

MSK Faculty



DIRECTOR

Mary Kate Kasler,
MSN, RN, DNP,
ACNP-BC



CO-DIRECTOR

Sandra D'Angelo, MD



CO-DIRECTOR

Kerry Williams,
MSN, RN, ANP-BC,
AOCNP®

PLANNING COMMITTEE

Linda D'Andrea, MSN, RN, PPCNP-BC, CPHON®
Madeline Merrill, MSN, RN, AGNP-BC
Yelena Shames, MSN, RN, ACNP-BC, CNRN®
Caroll Tipian, MSN, RN, DNP, AGACNP-BC
Joanne Wells, MSN, RN, ANP-BC, AOCNP®

FACULTY PRESENTERS

Gabrielle Arauz, MSN, RN, AGNP-BC, OCN®
Lauren Baker Banks, MD, PhD
Claudia Calderon, MSN, RN, AGPCNP-BC, OCN®
Joshua Drago, MD, MS
Ross Firestone, MD, PhD
Lynnette Henshaw, PharmD
Liubou Korzun, PA-C
Melanie Melendez, MSN, RN, AGPCNP-C, AOCNP®
Lavanya Mittal, MD
Katherine Nagel, MSN, RN, FNP-BC
Roisin O'Cearbhaill, MD
Rebecca Repetti, MSN, RN, ANP-BC, AOCNP®
Bianca Santomaso, MD, PhD
Alexander Shoushtari, MD
James Smithy, MD, MHS
Alice Wang, PharmD
Jessica Wilcox, MD



Memorial Sloan Kettering
Cancer Center

Schedule

TIME	SESSION/FACULTY
7:55 a.m.	Virtual Check-in (Zoom)
8:00 a.m.	Introduction and Welcome Mary Kate Kasler, MSN, RN, DNP, ACNP-BC
8:05 a.m.	Opening Remarks Sandra D'Angelo, MD

SESSION I

Fundamentals of Immunotherapy

Moderator: **Mary Kate Kasler, MSN, RN, DNP, ACNP-BC**

8:10 a.m.	Mechanism of Action of Checkpoint Blockade PD1, PDL1, CTLA-4 James Smithy, MD, MHS
8:40 a.m.	Discussion of Novel Checkpoint Inhibitors and Combination Therapy James Smithy, MD, MHS
9:00 a.m.	Q&A and Discussion

SESSION II

Clinical Application of Immune Checkpoint Inhibitors in Solid Tumor Malignancy

Moderator: **Joanne Wells, MSN, RN, ANP-BC, AOCNP®**

9:10 a.m.	Evolving Treatment Paradigms: Immunotherapy in Advanced Renal Cell Carcinoma Gabrielle Arauz, MSN, RN, AGNP-BC, OCN®
9:30 a.m.	Dostarlimab in MSI-High Gastrointestinal Cancers: Latest Data, Expansion Cohorts, and Basket Trial Insights Claudia Calderon, MSN, RN, AGPCNP-BC, OCN®
9:50 a.m.	Intrathecal Immunotherapy: A Novel Path in Treating Leptomeningeal Disease Jessica Wilcox, MD
10:10 a.m.	Exploring PD-1 Blockade with Cemiplimab and Bispecific Costimulatory Therapy in Advanced Solid Tumors with a Focus on Melanoma Alexander Shoushtari, MD
10:30 a.m.	Q&A and Discussion
10:40 a.m.	Break

SESSION III

Clinical Updates in Solid Tumor and Novel Immune Modulation

Moderator: **Yelena Shames, MSN, RN, ACNP-BC, CNRN®**

10:50 a.m.	Innovations in Small Cell Lung Cancer: DLL3 Agents and Adjuvant Durvalumab Rebecca Repetti, MSN, RN, ANP-BC, AOCNP®
11:10 a.m.	Breast Oncology: Using cfDNA to Forecast Immunotherapy Treatment Outcomes Joshua Drago, MD, MS
11:30 a.m.	The Role of T-Cell Therapy in Standard Care for Synovial Sarcoma Lauren Baker Banks, MD, PhD
11:50 a.m.	IL-2–Stimulating Agents from Early Drug Development Madeline Merrill, MSN, RN, AGNP-BC
12:10 p.m.	Q&A and Discussion
12:20 p.m.	Lunch Break

SESSION IV

Clinical Application of Immune Therapy in Hematologic Malignancy

Moderator: **Caroll Tipian, MSN, RN, DNP, AGACNP-BC**

1:00 p.m.	Checkpoint Inhibition as a Therapeutic Approach in Advanced Hodgkin Lymphoma Lynnette Henshaw, PharmD Alice Wang, PharmD
1:20 p.m.	Advancing Leukemia Care Through Immuno-Oncology Melanie Melendez, MSN, RN, AGPCNP-C, AOCNP®
1:40 p.m.	Targeting Multiple Myeloma with Bispecific Immune-Modulating Agents Ross Firestone, MD, PhD
2:00 p.m.	Q&A and Discussion

SESSION V

Introduction and Novel Approaches to T Cell Therapy

Moderator: **Madeline Merrill, MSN, RN, AGNP-BC**

2:10 p.m.	Understanding Chimeric Antigen Receptor (CAR) T-Cell Therapy Katherine Nagel, MSN, RN, FNP-BC
-----------	---

2:30 p.m.	Advancing CAR T-Cell Strategies and Combination Therapies to Improve Outcomes in Gynecologic Malignancies Roisin O’Cearbhaill, MD
2:50 p.m.	Q&A and Discussion
3:00 p.m.	Break
SESSION VI	
Clinical Management of Immunotherapy Toxicity	
Moderator: Kerry Williams, MSN, RN, ANP-BC, AOCNP®	
3:10 p.m.	Approaches to Immunotherapy-related Pneumonitis Management Liubou Korzun, PA-C
3:30 p.m.	Neurotoxicity in CAR T-Cell Therapy: Recognition and Management Bianca Santomasso, MD, PhD
3:50 p.m.	Clinical Approaches to Dermatologic Toxicity in Checkpoint Inhibitor Therapy Lavanya Mittal, MD
4:10 p.m.	Overview of Adverse Events in the Cell Therapy Patient: A Discussion of CRS, ICANS, and Prolonged Cytopenias Caroll Tipian, MSN, RN, DNP, AGACNP-BC
4:30 p.m.	Q&A and Discussion
4:40 p.m.	Closing Remarks Kerry Williams, MSN, RN, ANP-BC, AOCNP®
4:45 p.m.	Adjourn

All times listed in the schedule are in Eastern Standard Time (New York).



Memorial Sloan Kettering
Cancer Center

Registration

Physicians (MDs, PhDs, and DOs): \$249

Advanced Practice Providers: \$199

Nurses: \$149

Residents, Fellows, and Trainees: \$25*

Industry Professionals: \$435**

MSK Employees: Complimentary

Discounted registration is available for select groups. Additional details—including the registration link—can be found on our website:

msk.org/ImmunoOncSymposium

*The registration fee for residents, fellows, and trainees is non-refundable.

**An “industry professional” is defined as any individual, irrespective of their provider type (such as MDs, PhDs, APPs, RNs, etc.) that is employed by an ineligible company. Please review our Registration Policy for Industry Professionals for more information.

Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **7.50 AMA PRA Category 1 Credit(s)[™]**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.





Memorial Sloan Kettering
Cancer Center

Continuing Medical Education

msk.org/cme

CONNECT WITH MSK CME

Instagram ▶ [MSKcontinuingmedicaleducation](#)

LinkedIn ▶ [MSK-CME](#)

Facebook ▶ [MSKCME](#)

X ▶ [MSKCME](#)